Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Tyra Biosciences, Inc. (TYRA)

Tyra Biosciences Q2 net loss widens to $45.6 million; cash at $353.9 million

Negative Impact 3 of 5 earnings Written later

Tyra Biosciences reported a second-quarter 2026 net loss of $45.6 million, up from $28.1 million a year earlier, as research and development expenses rose to $39.2 million from $24.3 million. The company had $353.9 million in cash, cash equivalents and marketable securities at June 30, 2026, which it said should allow it to execute its plans into the second half of 2028. The filing also reports an amended at-the-market sales agreement with TD Securities (USA) LLC that allows sales of up to an additional $250.0 million of common stock.

Key points

  • Q2 2026 net loss was $45.6 million, or $0.69 per share, versus $28.1 million, or $0.47 per share, in Q2 2025.
  • R&D expenses were $39.2 million versus $24.3 million; G&A expenses were $9.8 million versus $7.1 million.
  • Cash, cash equivalents and marketable securities were $353.9 million at June 30, 2026; runway extends into the second half of 2028.
  • An amended ATM sales agreement with TD Securities (USA) LLC permits sales of up to an additional $250.0 million of common stock.

The filing

CompanyTyra Biosciences, Inc. (TYRA)
Form8-K, current report
Filed with the SECAug 4, 2026, 4:04 PM ET
Accession number0001193125-26-332752

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.